PCRX - Pacira Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
47.22
+0.27 (+0.59%)
As of 3:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close46.95
Open46.80
Bid47.40 x 800
Ask47.45 x 900
Day's Range46.80 - 47.60
52 Week Range26.95 - 47.60
Volume233,456
Avg. Volume633,129
Market Cap1.934B
Beta2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.28
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.69
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents12 hours ago

    Edited Transcript of PCRX earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Pacira Pharmaceuticals Inc Earnings Call

  • Pacira Pharmaceuticals (PCRX): Moving Average Crossover Alert
    Zacksyesterday

    Pacira Pharmaceuticals (PCRX): Moving Average Crossover Alert

    Pacira Pharmaceuticals, Inc. (PCRX) is looking like an interesting pick from a technical perspective

  • See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.

    Short interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 13.

  • GlobeNewswire6 days ago

    Pacira Pharmaceuticals to Present at the 2018 Wedbush Pacgrow Healthcare Conference

    Pacira Pharmaceuticals, Inc. (PCRX) today reported that it will present at the 2018 Wedbush Pacgrow Healthcare Conference at 9:45 AM ET on Tuesday, August 14, 2018. Pacira Pharmaceuticals, Inc. (PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.

  • Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
    Zacks8 days ago

    Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

    Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.

  • Associated Press12 days ago

    Pacira: 2Q Earnings Snapshot

    The Parsippany, New Jersey-based company said it had net income of 6 cents per share. Earnings, adjusted for one-time gains and costs, were 24 cents per share. The results surpassed Wall Street expectations. ...

  • See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
    Markit12 days ago

    See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.

    Short interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 13. Over the last one-month, outflows of investor capital in ETFs holding PCRX totaled $125 million.

  • GlobeNewswire12 days ago

    Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results

    --EXPAREL ® net product sales of $80.4 million up 15% over prior year second quarter---- Full-year EXPAREL net product sales guidance increased to $320 to $325 million---- Conference Call Today at 8:30 ...

  • Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?
    Zacks14 days ago

    Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?

    We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.

  • ACCESSWIRE15 days ago

    Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks

    Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Drugs - Generic stocks: The Medicines Co. (NASDAQ: MDCO), Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and SCYNEXIS Inc. (NASDAQ: SCYX).

  • Why Pacira Pharmaceuticals Stock Is on the Rise Today
    Motley Fool19 days ago

    Why Pacira Pharmaceuticals Stock Is on the Rise Today

    The company's shares are rallying today on an analyst upgrade.

  • GlobeNewswire20 days ago

    Pacira to Report Second Quarter 2018 Financial Results on Thursday August 2, 2018

    Pacira Pharmaceuticals, Inc. (PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 2, 2018. International callers may dial 1-720-545-0035 and use the same passcode. Pacira Pharmaceuticals, Inc. (PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients.

  • See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.

    Short interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 13. Over the last one-month, outflows of investor capital in ETFs holding PCRX totaled $1.40 billion.

  • Pacira Focused on Exparel Development Amid Competition
    Zacks29 days ago

    Pacira Focused on Exparel Development Amid Competition

    Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.

  • Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
    Zackslast month

    Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2

    Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.

  • GlobeNewswirelast month

    Pacira Reports Preliminary Net EXPAREL® Sales of $80.4 Million for Second Quarter of 2018

    Pacira Pharmaceuticals, Inc. (PCRX) today reported preliminary EXPAREL® (bupivacaine liposome injectable suspension) net product sales of $80.4 million for the second quarter of 2018, a 15 percent increase over EXPAREL net product sales of $69.8 million reported in the second quarter of 2017. “We are excited to report another consecutive quarter of accelerating sales growth, representing the expanding adoption of EXPAREL as an integral component of multimodal, non-opioid pain management strategies in a variety of surgical procedures,” said Dave Stack, chairman and chief executive officer of Pacira. “Our Johnson & Johnson partnership is flourishing and we are continuing to see a high level of engagement and enthusiasm around the launch of EXPAREL as the first long-acting, single-dose nerve block for upper extremity surgeries with increasing demand from new and existing accounts.

  • See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.

    Short interest is moderate for PCRX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 8. The net inflows of $2.85 billion over the last one-month into ETFs that hold PCRX are not among the highest of the last year and have been slowing.

  • ACCESSWIRElast month

    Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks

    Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.

  • Investors Are Undervaluing Pacira Pharmaceuticals Inc (NASDAQ:PCRX) By 43.7%
    Simply Wall St.2 months ago

    Investors Are Undervaluing Pacira Pharmaceuticals Inc (NASDAQ:PCRX) By 43.7%

    In this article I am going to calculate the intrinsic value of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by estimating the company’s future cash flows and discounting them to their present value.Read More...

  • MarketWatch2 months ago

    Heron Therapeutics stock rockets 30% on high hopes for post-surgery pain treatment

    Heron Therapeutics Inc. shares surged 30% Thursday, after the company announced positive developments for its treatment for postoperative pain that aims to reduce patient dependence on opioids. It then said that its HTX-011, which was the focus of the two studies, has won breakthrough therapy designation from the U.S. Food and Drug Administration. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam and is intended for the management of postoperative pain.

  • GlobeNewswire2 months ago

    Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China

    Pacira Pharmaceuticals, Inc. (PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement with Nuance, a China based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus nerve block.

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for Microchip Technology, New Jersey Resources, Brown-Forman, Pacira Pharmaceuticals, Team, and Solaris Oilfield Infrastructure — Fundamental Analysis, Key Performance Indications

    NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Microchip ...

  • GlobeNewswire2 months ago

    Aetna DocFind Directory Now Highlights Providers Offering Opioid Alternatives, Including EXPAREL®

    Pacira Pharmaceuticals, Inc. today announced further collaboration with Aetna, one of the nation’s leading diversified health care benefits companies. Aetna has updated its online provider directory, DocFind, to help members easily identify surgeons who are committed to offering opioid alternatives, including EXPAREL® (bupivacaine liposome injectable suspension), to manage postsurgical pain. This initiative builds off a national program launched by Pacira, Aetna, and the American Association of Oral and Maxillofacial Surgeons (AAOMS) in September 2017 aimed at reducing the number of opioid tablets prescribed to Aetna patients undergoing impacted wisdom tooth extractions through the use of EXPAREL.

  • Business Wire2 months ago

    MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS™) Collaborative to Minimize Opioid Use

    MEDNAX, Inc. (MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira Pharmaceuticals, Inc. (PCRX) to address the ongoing use of opioids during and after cesarean surgery by launching a national collaborative aimed at addressing the Quadruple Aim through the implementation of an Enhanced Recovery after Cesarean Surgery (ERACS™) program. The collaborative will be multi-disciplinary in nature, engaging the expertise of maternal-fetal medicine physicians, anesthesiologists, obstetricians and perioperative nurses to improve the patient experience as well as maternal and infant health, reduce the total cost of care and enhance provider satisfaction.

  • Pacira Pharmaceuticals (PCRX) Up 3.5% Since Earnings Report: Can It Continue?
    Zacks2 months ago

    Pacira Pharmaceuticals (PCRX) Up 3.5% Since Earnings Report: Can It Continue?

    Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.